123 related articles for article (PubMed ID: 38290205)
21. Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan.
Otsuru M; Yanamoto S; Yamada SI; Nakashiro K; Harazono Y; Kohgo T; Nakamura M; Nomura T; Kasamatsu A; Tanaka S; Kirita T; Kioi M; Ogawa M; Sasaki M; Ota Y; Umeda M
Int J Environ Res Public Health; 2023 Mar; 20(5):. PubMed ID: 36901553
[TBL] [Abstract][Full Text] [Related]
22. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
23. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis.
Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL
Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
Gao A; Pan X; Yang X; Lin Z
Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
[TBL] [Abstract][Full Text] [Related]
25. AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.
Chiu HW; Lee HL; Lee HH; Lu HW; Lin KY; Lin YF; Lin CH
J Transl Med; 2024 Jan; 22(1):13. PubMed ID: 38166970
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
27. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
28. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A
Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome.
Röhl L; Wellhausen J; Berszin M; Krücken I; Zebralla V; Pirlich M; Wiegand S; Dietz A; Wald T; Wichmann G
Front Immunol; 2023; 14():1237623. PubMed ID: 37849764
[TBL] [Abstract][Full Text] [Related]
31. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.
Saleh K; Auperin A; Martin N; Borcoman E; Torossian N; Iacob M; Ferrand FR; Khalife N; Baste N; Guigay J; Le Tourneau C; Daste A; Saada-Bouzid E; Even C
Eur J Cancer; 2021 Nov; 157():190-197. PubMed ID: 34536943
[TBL] [Abstract][Full Text] [Related]
33. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
[TBL] [Abstract][Full Text] [Related]
34. The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.
Haas M; Lein A; Fuereder T; Brkic FF; Schnoell J; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839241
[TBL] [Abstract][Full Text] [Related]
35. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
36. First‑line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study.
Cheng L; Chai C; Liu Y; Jiao J
Oncol Lett; 2024 Aug; 28(2):352. PubMed ID: 38872864
[TBL] [Abstract][Full Text] [Related]
37. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
[TBL] [Abstract][Full Text] [Related]
38. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma.
Chang KP; Wu CC; Fang KH; Tsai CY; Chang YL; Liu SC; Kao HK
Oral Oncol; 2013 Aug; 49(8):802-7. PubMed ID: 23769451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]